Early access
Sign in
Taking people in FrancePhase 2

Tests bimekizumab against topical steroids in early plaque psoriasis

Tests bimekizumab against topical steroids in adults with early plaque psoriasis.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nice
Where
Grenoble Cedex 9, Lyon Cedex 03, Marseille, Martigues, Nice, St Etienne Cedex 2, Toulon, and Villeurbanne Cedex, FranceSee the 8 sites
Registry title
Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
22 Jul 2025
Expected to end
1 Mar 2028
Type of study
Interventional
Record updated
5 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild plaque psoriasis, without psoriatic arthritis, who have a lesion on the elbows, knees or lower back. It compares bimekizumab with topical corticosteroids.

Age
18 years or older and under 45 years
Sex
Men and women
Disease stage
Mild plaque psoriasis with PASI above 2 and below 6, no psoriatic arthritis, at least one lesion on the elbows, knees or lower back. Disease must have lasted less than 6 months or more than 2 years.

Main reasons for not taking part

  • Pregnant or breast-feeding women
  • Women who could have children and do not use contraception or plan to become pregnant during the study
  • Psoriasis that is not plaque psoriasis
  • Any contraindication to bimekizumab or topical steroids, such as cancer in the last 5 years, active infection or latent tuberculosis
  • Taking part in another drug trial that could interfere with this evaluation

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Men and women
  • Patient willing and able to attend all study visits
  • ≥ 18 and <45 years
  • Plaque psoriasis without psoriatic arthritis
  • Patients with mild psoriasis PASI >2 and <6
  • Patient with at least one lesion on the elbows, the knees, or the lower back (additional lesions in other areas on top are allowed)
  • Disease duration less than 6 months (short duration psoriasis) or >2 years (long duration psoriasis)
  • For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed
  • Affiliation to a social security system
  • Signed informed consent

Who cannot take part

  • Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
  • Any contraindication to bimekizumab or topical steroids, including but not limited to history of cancer<5 years, active infection, latent tuberculosis
  • Pregnant or breast-feeding women. Or women with potential childbearing and not taking contraceptives or who plan to get pregnant during the study duration
  • Non plaque psoriasis
  • Vulnerable people: minors, adult under guardianship or deprived of freedom

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in France

  • Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
  • Hospital Edouard HerriotLyon Cedex 03, FranceTaking people
  • Hôpital Saint JosephMarseille, FranceTaking people
  • Du Docteur Ruer S.E.L.A.R.L.Martigues, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Universitaire De Saint EtienneSt Etienne Cedex 2, FranceTaking people
  • Centre Hospitalier Intercommunal Toulon / La Seine-Sur-MerToulon, FranceTaking people
  • Medipole Hopital PriveVilleurbanne Cedex, FranceTaking people

About the trial

What the trial wants to find out

To compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
EARLYPSO Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study
Plain-language title
Tests bimekizumab against topical steroids in early plaque psoriasisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-514647-29-01, who can take part
Record updated
5 August 2026